Cancer Monoclonal Antibodies Market to Grow at a 18.4 percent CAGR through 2031 SkyQuest Technology
TAK Stock | USD 12.95 0.29 2.19% |
About 61% of Takeda Pharmaceutical's investor base is looking to short. The analysis of overall sentiment of trading Takeda Pharmaceutical Co stock suggests that many investors are alarmed at this time. Takeda Pharmaceutical's investing sentiment shows overall attitude of investors towards Takeda Pharmaceutical Co.
Takeda |
The rising use of combination therapies and biosimilars is also slated to create new opportunities for cancer monoclonal antibodies companies.Westford, USA, Dec. 09, 2024 -- SkyQuest projects that the cancer monoclonal antibodies market size will attain a value of USD 337.92 billion by 2031, with a CAGR of 18.4 percent over the forecast period . High incidence of cancer and advancements in biotechnology are expected to bolster cancer monoclonal antibodies market growth over
Read at finance.yahoo.com
Takeda Pharmaceutical Fundamental Analysis
We analyze Takeda Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Takeda Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Takeda Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
Takeda Pharmaceutical is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Takeda Pharmaceutical Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Takeda Pharmaceutical stock to make a market-neutral strategy. Peer analysis of Takeda Pharmaceutical could also be used in its relative valuation, which is a method of valuing Takeda Pharmaceutical by comparing valuation metrics with similar companies.
Peers
Takeda Pharmaceutical Related Equities
PCRX | Pacira BioSciences, | 11.09 | ||||
ESPR | Esperion Therapeutics | 7.83 | ||||
NBIX | Neurocrine Biosciences | 1.58 | ||||
EVO | Evotec SE | 1.16 | ||||
BHC | Bausch Health | 0.64 | ||||
PBH | Prestige Brand | 0.51 | ||||
AMPH | Amphastar | 0.74 | ||||
ZTS | Zoetis | 1.03 | ||||
ELAN | Elanco Animal | 1.04 | ||||
SIGA | SIGA Technologies | 1.11 | ||||
COLL | Collegium Pharmaceutical | 1.29 | ||||
EBS | Emergent Biosolutions | 2.08 | ||||
VTRS | Viatris | 2.42 | ||||
TEVA | Teva Pharma | 2.56 | ||||
HLN | Haleon Plc | 4.11 | ||||
PAHC | Phibro Animal | 6.66 |
Check out Takeda Pharmaceutical Hype Analysis, Takeda Pharmaceutical Correlation and Takeda Pharmaceutical Performance. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.